Coeptis Therapeutics Holdings, Inc.
COEP
$13.21
-$0.445-3.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 219.08% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 219.08% | -- | |||
| Cost of Revenue | 0.00% | -- | |||
| Gross Profit | 778.53% | -- | |||
| SG&A Expenses | 10.66% | 138.35% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.61% | 90.54% | |||
| Operating Income | -11.44% | -87.63% | |||
| Income Before Tax | -26.71% | -13.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.71% | -13.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 120.26% | -65.86% | |||
| Net Income | -15.60% | -56.97% | |||
| EBIT | -11.44% | -87.63% | |||
| EBITDA | -12.34% | -96.74% | |||
| EPS Basic | 4.17% | -4.84% | |||
| Normalized Basic EPS | -0.57% | -70.94% | |||
| EPS Diluted | 4.17% | -4.84% | |||
| Normalized Diluted EPS | -0.57% | -70.94% | |||
| Average Basic Shares Outstanding | 20.62% | 49.72% | |||
| Average Diluted Shares Outstanding | 20.62% | 49.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||